Macrogenics (MGNX) Cash from Investing Activities Growth (3y) (2015 - 2026)
Macrogenics (MGNX) Cash from Investing Activities Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -29.84% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.24% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -22.09% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Macrogenics | 255.39 Mn | 188.87 Mn | - | 17.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.28% |
| Dec 31, 2025 | -125.07% |
| Sep 30, 2025 | -31.68% |
| Jun 30, 2025 | -53.74% |
| Mar 31, 2025 | 36.37% |
| Dec 31, 2024 | 71.67% |
| Sep 30, 2024 | 149.88% |
| Jun 30, 2024 | 50.85% |
| Mar 31, 2024 | 39.66% |
| Dec 31, 2023 | 64.05% |
| Sep 30, 2023 | 8.16% |
| Jun 30, 2023 | -68.30% |
| Mar 31, 2023 | 38.55% |
| Dec 31, 2022 | -40.25% |
| Sep 30, 2022 | 136.87% |
| Jun 30, 2022 | 62.32% |
| Mar 31, 2022 | 36.00% |
| Dec 31, 2021 | -32.01% |
| Sep 30, 2021 | -658.38% |
| Jun 30, 2021 | 55.62% |